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Abstract
Mice bearing Ehrlich tumor were administered 97Ru-chloride or 103Ru-chloride intravenously.
Examinations of various tissues indicated similar distributions by the two radionuclides. The lev-
els were higher in the lung, liver and kidney than in the tumor tissue. Rats bearing AH-130 tumor
were administered 103Ru-chloride intravenously. The 103Ru distribution in rats was highest in the
spleen, followed by the liver and kidney; however, the radioactive distribution in the tumor tissue
exceeded the muscle level by about 5-fold. Tumors were delineated in rats by scintigraphy. The
findings indicate that ruthenium radionuclides may be a useful clinical agent in the delineation of
some types of tumors. Ruthenium-97 would be favored in possible clinical usage due to its shorter
physical half-life and lower levels of gamma energy.
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Abstract: Mice bearing Ehrlich tumor were administered 97Ru_
chloride or I03Ru-chloride intravenously. Examinations of various
tissues indicated similar distributions by the two radionuclides. The
levels were higher in the lung, liver and kidney than in the tumor
tissue. Rats bearing AH-I30 tumor were administered I03Ru-chloride
intravenously. The I03Ru distribution in rats was highest in the
spleen, followed by the liver and kidney; however, the radioactive
distribution in the tumor tissue exceeded the muscle level by about
5-fold. Tumors were delineated in rats by scintigraphy. The findings
indicate that ruthenium radionuclides may be a useful clinical agent
in the delineation of some types of tumors. Ruthenium-97 would be
favored in possible clinical usage due to its shorter physical half-life
and lower levels of gamma energy.
Several effective radionuclides are currently available in clinical scmtI-
graphy (1-6) but the availability of other radionuclides would be useful in
some situations. Ruthenium red is known to have a selective affinity to
glycoproteins and polysaccaharides of organellas, cells and tissues (7-9).
Transformed cancer cells are stained more intensely with ruthenium red than
normal cells (10). The mechanism of this binding affinity has not yet been
clarified, but the possibility of binding by the ruthenium ion itself cannot be
ruled out. The present study examines the tissue distributions of 10 3Ru in
tumor-bearing mice and rats and 97Ru in tumor-bearing mice. A subsequent
report will cover clinical trials with these radionuclides.
MATERIALS AND METHODS
Ruthenium-97 and I03Ru as chloride in hydrochloride solution (manufactur-
ed by New England Nuclear Laboratories and the Radiochemical Center, re-
spectively) were purchased from the Japanese Isotope Society. Ruthenium-103
had a carrier which contained 1.1 mg of Ru per ml and 97Ru was carrier free.
Each radionuclide in hydrochloride was adjusted to a pH of 1.5-2.0 with sodium
hydroxide, since precipitation occurs at higher pH. The solution was passed
through a Millipore filter for sterilization prior to use.
Animals used were 20 male mice of the ddy strain weighing about 20 g and
4 male rats of the Donryu strain weighing about 200g. Each experimental group
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consisted of 4 animals.
Ehrlich ascites tumor cells were transplanted subcutaneously in the lower
thigh of mice. AH.130 ascites tumor cells were transplanted subcutaneously in
the lower thigh of rats. These tumor cells were previously cultured over a
long period of time in our laboratories. The experiment was initiated when
the tumors grew to about 2 cm in diameter. Inflammation was induced artifi.
cially with croton oil injected subcutaneously in the lower thigh. In mice,
97Ru.chloride solution or l03Ru.chloride solution was administered intravenously
in the tail vein at a dose of 1 ,uCi per g of body weight. In rats, l03Ru·chloride
solution was administered in the same manner, at a dose of 0.5 ,uCi per g of body
weight. The animals were sacrificed by severing the carotid artery. Mice
treated with l03Ru were killed at 1,24 and 72 hours after radionuclide injection;
mice treated with 97Ru were killed at 24 and 72 hours after injection. Rats were
killed at 48 hours after l03Ru injection. Blood and 0.2 to 0.5 g of spleen,
liver, kidney, lung, and muscle (lower thigh) were collected from all animals
and weighed wet. In addition, 0.2 to 0.5 g of rat bone (femur with bone
marrow), heart, small intestine, testicle, subcutaneous fat (abdominal wall)
and inflammatory tissue (lower thigh) were collected and weighed wet. The
radioactivity of each tissue was measured with an auto·well scintillation
counter (Aloka). The residual body radioactivity after radionuclide injection
was measured with a scinticamera (pho/Gamma III, Nuclear Chicago Labora.
tories) at 1, 2, 6 and 11 days in the I03Ru group and at 1, 3, 6 and 10 days in the
97Ru group, under fixed geometical conditions. The biological half.life was
calculated. Scinticamera was connected with a Toshiba data processor (DAP.
5000) for scintigraphy.
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Fig. 1. Whole body ruthenium radionuclide retention percentages at various
time periods in mice bearing Ehrlich tumor. Dotted lines indicate the biological
half-life components calculated from whole body counts. The linear sections of
the solid lines show the long-life phase. The short-life phase was calculated by
subtracting the extrapolation of the long-life phase from the solid line.
2
Acta Medica Okayama, Vol. 29 [1975], Iss. 6, Art. 5
http://escholarship.lib.okayama-u.ac.jp/amo/vol29/iss6/5
Ruthenium Radionuclides 433
Tissue
RESULTS
Fig. 1 shows the radioactive retention percentages of 10 3Ru and 97Ru in
mice. The short-life phase of biological half-life in 103Ru was estimated to
be about 14 hours and the long-life phase was about 20 days; in 97Ru, the
short-life phase was estimated to be about 16 hours and the long-life phase
was about 16 days.
TABLE 1. TUMOR-TO-T1SSUE RATIOS FOR 97Ru AND l03Ru IN MICE
BEARING EHRLICH SUBCUTANEOUS TUMOR
Radio- Time .(hr)
nuclide ~ft.er I:V. ---------------------------
InjectIOn Blood Lung Liver Spleen Kidney Muscle
l03Ru_
chloride
97Ru_
chloride
1
24
72
24
72
O. 18±0. 02 0.41 ±O. 05 O. 53±0. 11 1. 29±0. 28 O. 49±0. 07 2.27 ±O. 45
O. 46±0. 06 O. 53±0. 06 O. 29±0. 04 O. 9O±0. 14 O. 29±0. 05 1. 85±0. 46
1. 21 ±O. 17 O. 70±0. 12 0.27 ±O. 02 O. 9O±0. 15 O. 30±0. 02 1. 93±0. 50
O. 86±0. 01 O. 39±0. 05 O. 26±0. 04 1. 47 ±O. 18 O. 19±0. 02 1. 35±0. 25
1. 48±0. 28 O. 48±0. 02 O. 19±0. 02 1. 20±0. 27 O. 14±0. 01 1. 12±0. 05
The tissue ratios are presented as mean ± S. D. in 4 animals per group.
Table 1 shows the radioactive ratio~ of tumor-to-tissue in mice at three
times periods after injection. Both 97Ru and 103Ru indicated similar distri-
butions. The radioactivity (count/g wet weight) in blood decreased gradually
to a value lower than in the tumor at 72 hours after injection. The radio-
activity of the lung, liver and kidney was higher than in the tumor. Tumor
radioactivity was higher than in the spleen and muscle.
TABLE 2. TUMOR-TO-TISSUE RATIOS FOR l03Ru IN RATS BEARING SOLID
TUMOR (AH-130l 48 HOURS AFTER I. V. INJECTION
Tissue
Spleen
Liver
Kidney
Lung
Blood
Bone (femur with bone marrow)
Inflammatory tissue (lower thigh)
Heart
Small intestine
Testicle
Muscle (lower thigh)
Subcutaneous fat (abdominal wall)
Ratio*
0.36±0.1O
O. 52±0. 12
0.81 ±O. 23
1. 28±0. 24
1. 72±0. 58
2.02
2.46
3. 17±0. 74
3. 78±0. 91
4. 17±0. 79
5. 82±3. 21
10. 42±2. 68
* The tissue values are presented as mean I. S. D. in 4 animals, except for the bone and
inflammatory tissue that are based on one case each.
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Table 2 shows the ]0 3Ru radioactive ratios of tumor-to-tissue in rats at48 hours after injection of 10 3Ru-chloride. The ratio of tumor-to-musc1e was5.82. Positive-delineation of the AH-130 tumor was obtained by scintigraphy(Fig. 2).
Fig. 2. Rat AH-130 solid subcutaneous tumor 48 hours after injection of l03Ru_
chloride. A, Scintigram showing positive-delineation of tumor in the lower right
thigh (arrow). B, Digital scintigraphy of the same areas shown in Fig. 2A. Density
of over 50% (white areas), density between 35% to 50% (light gray areas) and den-
sity less than 35% (dark gray areas).
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DISCUSSION
Ruthenium-97, l03Ru and l05Ru are among ruthenium radionuclides
those gamma emissions can be measured externally. Ruthenium-l03 has a
physical half-life of 39.5 days, undergoes beta decay and emits gamma rays
at 0.497 Mev (88%) and at 0.61 MeV. Ruthenium~97 has a physical half-life
of 2.9 days, decays by electron capture and emits gamma rays at 0.018 MeV,
0.215MeV (91 %) and 0.32 MeV. Ruthenium-97 is, therefore, more suitable
for clinical practice.
Other data is available on the biological behavior of radioactive ruthe-
nium (11-18). In clinical applications of radionuclides the biological half-life
is an extremely important factor. The short-life phase of biological half-life
following injection in chloride form was about 16 hours for 97Ru and about
14 hours for l03Ru. The long-life phase was about 16 days for 9:TRu and
about 20 days for l03Ru. The reasons for these differences are unclear, but
the presence or absence of a carrier may be an important factor (19).
As the radioactive clearance. of Rn-radionuclide from the blood is slow,
the tUmor is likely to be surrounded with a blood peol during scintigraphy.
The initiation of scanning should be determined by conditions of blood clear-
ance.From our experimental results with Rn-radionuclides, the optimal
starting period appears to be from 3 to 6 days after the administration of the
nuclide.
The presence of abundant radioactivity in the liver and spleen indicates
the difficulty of scanning for abdominal tumors. Furthermore, variations in
uptake were present in the spleens of mice and rats. It is possible that splenic
hematopoietic differences of mice and rats may be a factor contributing to this
variation (20) ..
In the present investigation, rats bearing AH-130 tumors showed a l03Ru
uptake that was about five times higher than muscle, and the tumor was
delineated by scintigraphy. Although further investigations on Ru-radio-
nuclides are required, especially on the complex forms for injection, the
results of this study suggest on preliminary basis that 97Ru may be clinically
useful for delineating certain kinds of tumorS.
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